CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2007-08-31): Prolonged interferon therapy may prevent progression of hepatitis C to cancer

Clinical

Prolonged interferon therapy may prevent progression of hepatitis C to cancer

Last Updated: 2007-08-31 15:20:29 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Prolonged interferon therapy reduces the progression of chronic hepatitis C virus (HCV) infection to hepatocellular carcinoma (HCC), according to a report in the August issue of the Journal of Medical Virology.

Dr. Yasuji Arase and associates from Toranomon Hospital in Tokyo evaluated the effect of long-term interferon therapy on the development of HCC in 120 patients aged 60 years and older with chronic HCV-related hepatitis or cirrhosis.

These patients received 3 million units natural interferon-alpha two or three times weekly for up to 15.5 years. Another 240 similar patients treated with herbal medicines served as controls.

Serum alpha-fetoprotein (AFP) and transaminase levels decreased significantly in patients treated with interferon compared with patients not treated with interferon, the authors report.

The cumulative rates of HCC were significantly lower in the interferon group than in the interferon group at 5 years (5.9% versus 13.7%, respectively) and at 10 years (17.1% versus 32.8%, respectively), the report indicates.

In a multivariate analysis, not being treated with interferon, having advanced histological staging, and having serum AFP levels above 10 ng/mL after initiation of treatment were independently associated with a higher risk of progression to HCC.

Only 9 of 120 interferon-treated patients discontinued therapy because of adverse events.

Based on these findings, the researchers conclude, "Long-term interferon treatment for protection against HCC could be recommended for patients with elevated AFP levels and/or severe liver fibrosis who can tolerate interferon-related side effects."

J Med Virol 2007;79:1095-1102.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.